Selective RET inhibition with selpercatinib has demonstrated durable efficacy with low-grade toxicity in medullary thyroid cancer patients harbouring RET mutation, according to the results of a phase I–II trial.
Moderate-intensity aerobic and resistance exercises may not be enough to attenuate the negative effects of androgen deprivation therapy (ADT) on metabolic markers and bone mineral density in older men with prostate cancer, a recent study has found.
While the Managing Cancer and Living Meaningfully (CALM) therapy leads to improvements in depressive symptoms over time, it does not appear to be better than supportive psycho-oncological counselling intervention, a new trial has found.
Treatment with the oral combination of 17β-oestradiol and progesterone in postmenopausal women does not appear to be related to abnormal mammograms, and the incidence of breast tenderness is low as compared with the rates reported in other hormone therapy studies, according to data from the phase III trial REPLENISH.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.